Novel Therapeutic Targets of Pulmonary Hypertension

Novel Therapeutic Targets of Pulmonary Hypertension.

Pulmonary hypertension (PH) is a fatal disease caused by small pulmonary artery obstruction by vascular proliferation and remodeling. PH is characterized by elevated pulmonary arterial pressure and increased pulmonary vascular resistance, frequently leading to right heart failure and death. PH is defined as a mean pulmonary arterial pressure ≥25 mm Hg at rest with right heart catheterization. T...

Novel therapeutic perspectives in pulmonary arterial hypertension.

Pulmonary arterial hypertension (PAH) refers to a disease spectrum of the small pulmonary arteries leading to a progressive increase in pulmonary vascular resistance, right ventricular failure and, ultimately, death [1]. It is usually accepted that a vasoconstrictive factor is involved in PAH [2]. However, pure vasodilators, such as calcium channel blockers, have so far provided little or no be...

Reactive oxygen species as therapeutic targets in pulmonary hypertension.

Pulmonary hypertension (PH) is characterized by a progressive elevation of pulmonary arterial pressure due to alterations of both pulmonary vascular structure and function. This disease is rare but life-threatening, leading to the development of right heart failure. Current PH treatments, designed to target altered pulmonary vascular reactivity, include vasodilating prostanoids, phosphodiestera...

Fibrocytes: potential new therapeutic targets for pulmonary hypertension?

Pulmonary arterial hypertension: therapeutic algorithm.

The numerous controlled clinical trials performed recently in pulmonary arterial hypertension (PAH) can allow us to abandon a clinical-based treatment strategy and adopt an evidence-based therapy. The treatment algorithm is restricted to patients in NYHA class III or IV. The different treatments have been evaluated mainly in sporadic, idiopathic PAH and in PAH associated with scleroderma or to ...